These findings, supported by TCGA data, indicate that CBX4 upregulation serves as a marker associated with malignant clinicopathological features and unfavorable prognosis in GC, suggesting its potential role as a driver of tumor aggressiveness. Here, CBX4 is linked to gastric cancer.